Ovid Therapeutics (OVID) Net Equity Issued and Repurchased (2019 - 2026)

Ovid Therapeutics (OVID) posted Net Equity Issued and Repurchased of $2.4 million for Q1 2026, up 11000.68% on a QoQ basis from $21314.0 in Q4 2021.

Ovid Therapeutics (OVID) Net Equity Issued and Repurchased (2019 - 2026) Analysis & Trends

Ovid Therapeutics' Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $2.4 million for Q1 2026.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (up 11100.68% YoY) and the FY2020 annual result came in at $46.7 million, up 109.68% from the prior year.
Net Equity Issued and Repurchased was $2.4 million for Q1 2026 at Ovid Therapeutics, up from $21314.0 in the prior quarter.
Across five years, Net Equity Issued and Repurchased topped out at $2.4 million in Q1 2026 and bottomed at $2.4 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	163.10 Mn
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	141.90 Mn
10	Ovid Therapeutics	118.66 Mn	-36.86 Mn	-	2.37 Mn

Download Data